Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness.

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular ...

Fast Track status aims to accelerate development of an autologous dendritic cell immunotherapy for advanced cutaneous melanoma with limited durable benefit from current standards in many patients.

Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

Inside TIL therapy: daily hospital routines, caregiver support, chemo and infusion steps, and what recovery questions patients ask most. Interleukin-2 (IL-2) is often the most challenging part of ...

CURE spoke with Dr. Michael E. Kasper, medical director of radiation oncology at the Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital.

A mother reflects on the "tethered heart" of caregiving, sharing her journey through her son’s rare cancer and offering solidarity to all mothers.

Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...